person

Peter N.

Country
Germany
Department
FAZIT – Fabry-Zentrum für interdisziplinäre Therapie

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
3
Sites with multiple studies

Has run more than one trial at 3 of 94 partner sites.

Specializations

Rare Genetic Disorders

This investigator specializes in Fabry disease, a rare X-linked lysosomal storage disorder. Their research encompasses therapeutic interventions including gene therapy approaches and oral treatments for managing this inherited condition.

  • Gene Therapy Development
  • Long-term Disease Management
  • Lysosomal Storage Disorders

Their work focuses on evaluating novel therapeutic options for patients with Fabry disease, including monitoring long-term safety outcomes.

Cardiovascular Medicine

The investigator conducts research in acute cardiac conditions, particularly focusing on ST-Elevation Myocardial Infarction (STEMI). Their work involves investigating therapeutic interventions for patients undergoing primary percutaneous coronary intervention.

  • Acute Cardiac Care
  • Myocardial Infarction Management
  • Cardiovascular Mortality Prevention

Their research extends to examining treatments aimed at reducing heart failure events and improving outcomes in anterior STEMI patients.

Therapeutic Development

The investigator evaluates novel therapeutic compounds and treatment approaches, with expertise in both traditional pharmaceutical interventions and advanced therapy medicinal products.

  • Safety and Tolerability Studies
  • Long-term Treatment Outcomes
  • Clinical Trial Design

Their research encompasses both rare disease therapeutics and cardiovascular interventions, focusing on patient safety and treatment efficacy.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.